Impurity identification and

The authors would like to thank Vincent Bobin for the solubility data for Compound A. The authors would also like to thank the following individuals for their work on Compound B described in this chapter Daniel Gierer for manufacture of the placebo tablets Amy Orce for her work on the extraneous syringe peak Thomas Sharp, George Horan, and Ronald Morris for their work on impurity identification and Cheryl Kirkman, Heidi O Donnell, Britt-Marie Otano, Doreathea Roberts, J. Sean Space, and Gregory Steeno for their work on the small volume dissolution method. In addition, the authors would like to thank Amanda Deal and Kelly Field for their work on the HPLC purity method development for the fixed combination tablet. 

Many pitfalls await the unwary. Here is a short list, compiled from more detailed considerations by Bunnett.8 One should properly identify the reactants. In particular, does each retain its integrity in the reaction medium A spectroscopic measurement may answer this. The identities of the products cannot be assumed, and both a qualitative identification and a quantitative assay are in order. Pure materials are a must—reagents, salts, buffers, and solvent must be of top quality. Careful purification is always worth one s time, since much more is lost if all the work needs repeating. The avoidance of trace impurities is not always easy. If data are irreproducible, this possibility must be considered. Reactions run in the absence of oxygen (air) may be in order, even if the reactants and products are air-stable. Doing a duplicate experiment, using a spent reaction solution from the first run as the reaction medium, may tell whether the products have an effect or if some trace impurity that altered the rate has been expended. 

It appears that purification of commercially available solvents is sometimes required for the complete elimination of impurity resonances. Occasionally, these impurities may be turned into advantage, as in the case of C2D2CI4 where the (known) C2DHCI4 content may be used as an internal standard for quantitation. Thus, removal of every impurity peak is not always essential for identification and quantitative analysis of stabilisers in PE. Determination of the concentration of additives in a polymer sample can also be accomplished by incorporation of an internal NMR standard to the dissolution prepared for analysis. The internal standard (preferably aromatic) should be stable at the temperature of the NMR experiment, and could be any high-boiling compound which does not generate conflicting NMR resonances, and for which the proton spin-lattice relaxation times are known. 1,3,5-Trichlorobenzene meets the requirements for an internal NMR standard [48]. The concentration should be comparable to that of the analytes to be determined. 

The nature and the relative amounts in which the components of materials have to be detected in different analytical studies varies greatly from the identification and determination of the few major elements that make up a material, to the wide range, often in almost vanishing concentrations, of impurities. From a practical point of view and regardless of the objective of, or the type of information required from an analysis, most analytical procedures entail a sequence of three main operations ... 

For non-compendial procedures, the performance parameters that should be determined in validation studies include specificity/selectivity, linearity, accuracy, precision (repeatability and intermediate precision), detection limit (DL), quantitation limit (QL), range, ruggedness, and robustness [6]. Other method validation information, such as the stability of analytical sample preparations, degradation/ stress studies, legible reproductions of representative instrumental output, identification and characterization of possible impurities, should be included [7], The parameters that are required to be validated depend on the type of analyses, so therefore different test methods require different validation schemes. 

Most early publications on bacterial polysaccharides were concerned with impure products and poorly-described organisms. Many more recent papers are of limited value also, due to low yields, lack of characterization of products and arbitrary interpretations of data. Low yields of methylated polysaccharides may be due to degradation of the bacterial polysaccharide during methylation, or to degradation of the hydrolytic products of the methylated polysaccharide (to form methyl levulinate, etc.46). The great importance of (a) complete methylation of polysaccharide products prior to structural determination by hydrolysis and (6) quantitative identification of the hydrolytic products, has been emphasized previously. Other difficulties in end group analysis have been discussed recently.7... 

Identification and structural analysis of organic compounds. Determination of trace impurities in a wide range of inorganic materials (spark source mass spectrometry). 

Manufacturing identification Impurity and degradant identification Identification and quantitation No Low... 

So-called street drugs for identification of principal components, impurities, adulterants, and cutting agents in order to establish the method of synthesis, to compare the samples seized from users with those from dealers, as well as for comparative analysis or so-called profiling to find out the source of the material. 

Solutions to practical problems rarely depend upon a single technique or a single approach. The following example of an impurity identification in a pharmaceutical product illustrates the key role that LC-MS can play in such an investigation, but also illustrates the limitations of the technique. The identification of this impurity has been published elsewhere in complete detail [75]. The problem and solution is summarized here. The impurity, designated as H3, was observed at 0.15% in a bulk lot of the drug substance in the structure below. The impurity required identification before the bulk lot could be released for use in further studies. 

NFPA developed Standard 704 as a tool for identification and evaluation of potential hazards during emergency response, not for application to chemical process safety. The instability rating is a part of this standard. It was not intended to be used to measure reactivity, but rather to measure the inherent instability of a pure substance or product under conditions expected for product storage. The instability rating does not measure the tendency of a substance or compound to react with other substances or any other process-specific factors, such as operating temperature, pressure, quantity handled, chemical concentration, impurities with catalytic effects, and compatibility with other chemicals onsite. 

Accurate and meaningful conductance data may be obtained only in systems where the solvent and solute are free of foreign materials. Soluble conducting impurities in either one are obvious sources of error less obvious are non-conducting impurities that effect solvation by competition with the solvent for coordination sites on ions. Purification of materials is always onerous, and is frequently aggravated by analytical difficulties in identification and measurement of trace contaminants. 

ELISAs can be used for identification and quantitation of a biopharmaceutical product or for quantitation of impurities or contaminants as discussed previously. They can be used throughout the manufacturing process as well as in quality control or the product release stage just as they are used in all the other stages of product development. To be used for quality control, GMP practices must be followed. All methods need to be validated so that the assay s performance is documented. ELISAs should have internal quality controls to monitor assay... 

ELISAs can be used for identification and quantitation of the product as well as impurities in the various purification steps (as discussed previously). They can be used to document the removal of known impurities and contaminants, and in process validation to demonstrate batch-to-batch consistency of manufacturing. 

Compound purity (or integrity testing) is important to ensure purity in the early stages because erroneous activity or toxicity results may be obtained by impure compounds, ft is initiated during hit identification and continued into lead and candidate selection. 

Regulatory bodies such as the Food and Drug Administration (FDA) in the United States require the identification of all impurities above the 0.1% level in formulated pharmaceuticals. Once identified, the structure of the impurity is typically confirmed through synthesis to provide absolute structure identification and for use as standards in subsequent quality assurance analyses. Together, LC-MS and LC-NMR play important roles in stability testing. For example, parallel analysis by LC-NMR and LC-MS was used for the rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid, which is marketed for the treatment of acute ulcerative colitis and Chron s disease [57]. In another study, Fukutsu et al. [58] used a combination... 

Impurity testing is pivotal in pharmaceutical development for establishing drug safety and quality. In this chapter, an overview of impnrity evaluations of drug substances and products by HPLC is presented from both the laboratory and regulatory standpoints. Concepts from the development of impurity profiles to the final establishment of public specifications are described. Useful strategies in the identification and quantification of impurities and degradation products are summarized with practical examples to illustrate impurity method development. 

The concurrent identification and quantification of organic impurities is a principal use of liquid chromatography in the pharmaceutical industry. However, the application of liquid chromatography to this task highlights a weakness of this technique when compared to gas chromatography specifically, the lack of a universal detector. Great strides have been made to create detectors and hyphenated techniques to address these problems. However, multiple detectors and analytical procedures may be necessary to accurately and specifically identify and quantify the impurities in complex systems. 

Once a database is established, it is made available to other laboratories through the company s secured intranet, so that the information therein can be updated, retrieved and reviewed. The resulting structural library can be referenced throughout the lifetime of the drug for rapid identification of impurities, degradants, and metabolites. 

Various international pharmacopoeias help assure the quality of drugs worldwide. These pharmacopoeias constantly review and revise their monographs. A different impurity profile can be anticipated if a drug s production process is changed this results in the development of new analytical methods that need to be incorporated in the pharmacopoeias. In earlier editions, color reactions were performed for identification and purity evaluation purposes. 

---